These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 38203475)
1. Multiple Genomic Alterations, Including a Novel Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475 [TBL] [Abstract][Full Text] [Related]
2. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review. Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479 [TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126 [TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report. Dang X; Zhou D; Meng L; Bi L J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792 [TBL] [Abstract][Full Text] [Related]
5. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Lee SS; McCue D; Pemmaraju N Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559 [TBL] [Abstract][Full Text] [Related]
8. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Alfayez M; Konopleva M; Pemmaraju N Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379 [No Abstract] [Full Text] [Related]
9. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355 [TBL] [Abstract][Full Text] [Related]
10. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Adimora IJ; Wilson NR; Pemmaraju N Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525 [TBL] [Abstract][Full Text] [Related]
11. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm. Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907 [TBL] [Abstract][Full Text] [Related]
17. [Enhancer hijacking via disease-specific chromosomal translocation in blastic plasmacytoid dendritic cell neoplasm]. Kubota S Rinsho Ketsueki; 2020; 61(1):47-51. PubMed ID: 32023603 [TBL] [Abstract][Full Text] [Related]
18. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081 [TBL] [Abstract][Full Text] [Related]
19. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Economides MP; McCue D; Lane AA; Pemmaraju N Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247 [No Abstract] [Full Text] [Related]
20. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report. Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]